Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 14/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982276 | 0.95 | MAPK14 (0.53) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL4982278 | 0.95 | MAPK14 (0.53) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL7046680 | 0.89 | MAPK14 (0.46) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL7046683 | 0.89 | MAPK14 (0.46) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL7051078 | 0.86 | MAPK14 (0.51) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL7046684 | 0.85 | MAPK14 (0.46) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL7046364 | 0.84 | MAPK14 (0.47) | MAPK14TGFBR1TGFBR2MAPK13MAPK12 | |
| SCHEMBL6949309 | 0.80 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CSNK1E | |
| SCHEMBL6578852 | 0.79 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11CSNK1E | |
| SCHEMBL4984293 | 0.78 | MAPK14 (0.56) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069243-A1 | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-6569871-B1 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20030069243-A1 | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069243-A1 | Novel substituted imidazole compounds | CREBBP, MAPKAPK2, CDC42BPB | MAPK14 92/4885TGFBR1 1384/4885TGFBR2 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.